GB201908780D0 - Melanoma biomarkers - Google Patents

Melanoma biomarkers

Info

Publication number
GB201908780D0
GB201908780D0 GBGB1908780.8A GB201908780A GB201908780D0 GB 201908780 D0 GB201908780 D0 GB 201908780D0 GB 201908780 A GB201908780 A GB 201908780A GB 201908780 D0 GB201908780 D0 GB 201908780D0
Authority
GB
United Kingdom
Prior art keywords
melanoma biomarkers
biomarkers
melanoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1908780.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protagen GmbH
Original Assignee
Protagen GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protagen GmbH filed Critical Protagen GmbH
Priority to GBGB1908780.8A priority Critical patent/GB201908780D0/en
Publication of GB201908780D0 publication Critical patent/GB201908780D0/en
Priority to EP20734358.3A priority patent/EP3987289A1/en
Priority to JP2021575276A priority patent/JP2022537339A/ja
Priority to PCT/EP2020/067245 priority patent/WO2020254658A1/en
Priority to CN202080058690.XA priority patent/CN115176159A/zh
Priority to US17/596,683 priority patent/US20220317125A1/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1908780.8A 2019-06-19 2019-06-19 Melanoma biomarkers Ceased GB201908780D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB1908780.8A GB201908780D0 (en) 2019-06-19 2019-06-19 Melanoma biomarkers
EP20734358.3A EP3987289A1 (en) 2019-06-19 2020-06-19 Melanoma biomarkers
JP2021575276A JP2022537339A (ja) 2019-06-19 2020-06-19 メラノーマバイオマーカー
PCT/EP2020/067245 WO2020254658A1 (en) 2019-06-19 2020-06-19 Melanoma biomarkers
CN202080058690.XA CN115176159A (zh) 2019-06-19 2020-06-19 黑素瘤生物标志物
US17/596,683 US20220317125A1 (en) 2019-06-19 2020-06-19 Melanoma biomarkers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1908780.8A GB201908780D0 (en) 2019-06-19 2019-06-19 Melanoma biomarkers

Publications (1)

Publication Number Publication Date
GB201908780D0 true GB201908780D0 (en) 2019-07-31

Family

ID=67432302

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1908780.8A Ceased GB201908780D0 (en) 2019-06-19 2019-06-19 Melanoma biomarkers

Country Status (6)

Country Link
US (1) US20220317125A1 (enExample)
EP (1) EP3987289A1 (enExample)
JP (1) JP2022537339A (enExample)
CN (1) CN115176159A (enExample)
GB (1) GB201908780D0 (enExample)
WO (1) WO2020254658A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024505333A (ja) 2020-12-21 2024-02-06 フリーノム ホールディングス，インク． 結腸細胞増殖障害の早期検出のためのマーカー
CN114910647A (zh) * 2022-05-07 2022-08-16 浙江大学 细丝蛋白-A-IgG抗体在制备检测血管内皮损伤试剂盒中的应用
KR102534243B1 (ko) * 2022-12-05 2023-05-31 넥스탭 주식회사 Eomes 단백질을 표적으로 하는 인터페론-γ 조절 물질의 확인방법 및 이 물질을 포함하는 의약
CN116159127B (zh) * 2023-01-17 2024-04-02 西安交通大学医学院第一附属医院 酸性核糖体蛋白p2在治疗焦虑症中的应用
CN118311257B (zh) * 2024-03-22 2025-03-28 安徽师范大学 子宫颈神经内分泌癌标志物在制备子宫颈神经内分泌癌诊断试剂中的应用
CN118604339A (zh) * 2024-05-09 2024-09-06 深圳市第二人民医院(深圳市转化医学研究院) Snrpa蛋白检测试剂在制备肝癌诊断试剂盒中的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012220872A1 (en) * 2011-02-22 2013-09-12 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers
EP2806274A1 (en) * 2013-05-24 2014-11-26 AIT Austrian Institute of Technology GmbH Lung cancer diagnostic method and means
WO2019115480A1 (en) * 2017-12-12 2019-06-20 Protagen Ag Melanoma checkpoint inhibitor detection and treatment

Also Published As

Publication number Publication date
CN115176159A (zh) 2022-10-11
US20220317125A1 (en) 2022-10-06
WO2020254658A1 (en) 2020-12-24
EP3987289A1 (en) 2022-04-27
JP2022537339A (ja) 2022-08-25

Similar Documents

Publication Publication Date Title
GB201908780D0 (en) Melanoma biomarkers
GB201703058D0 (en) Biomarkers
IL286258A (en) Carrying assembly
GB201902077D0 (en) Biomarkers
GB201900677D0 (en) Biomarkers
GB201704267D0 (en) Novel biomarker
GB201804648D0 (en) Combination biomarker
SG11202110589PA (en) Biomarkers for selinexor
SG11202105172PA (en) Biomarkers for cardiovascular events
GB201703123D0 (en) Biomarkers
GB201814807D0 (en) Dementia Biomarkers
GB202014190D0 (en) Biomarkers
GB201811093D0 (en) Biomarker
GB202103951D0 (en) Biomarkers
GB201913846D0 (en) Biomarker
GB201912154D0 (en) Biomarker
GB201911078D0 (en) Biomarker
GB202015056D0 (en) Biomarkers
GB201915228D0 (en) Biomarkers
GB201902070D0 (en) Biomarkers
GB201914183D0 (en) Biomarker
GB201913612D0 (en) Biomarker
GB202114655D0 (en) Biomarkers
GB202111201D0 (en) Biomarkers
GB202103140D0 (en) Biomarkers

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)